NYSE:GKOS

Glaukos Competitors

$83.13
-2.71 (-3.16 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$80.34
Now: $83.13
$85.81
50-Day Range
$79.95
MA: $87.71
$97.42
52-Week Range
$31.42
Now: $83.13
$99.00
Volume386,803 shs
Average Volume443,021 shs
Market Capitalization$3.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.87

Competitors

Glaukos (NYSE:GKOS) Vs. ABMD, NVCR, PEN, HRC, GMED, and HAE

Should you be buying GKOS stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Glaukos, including Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), and Haemonetics (HAE).

Glaukos (NYSE:GKOS) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Glaukos and Abiomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Glaukos-33.61%-7.99%-5.87%
Abiomed25.89%15.34%13.51%

Institutional & Insider Ownership

94.0% of Abiomed shares are owned by institutional investors. 8.7% of Glaukos shares are owned by company insiders. Comparatively, 3.4% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Glaukos has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glaukos and Abiomed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Glaukos16102.00
Abiomed12202.20

Glaukos presently has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. Abiomed has a consensus target price of $348.3333, suggesting a potential upside of 4.35%. Given Abiomed's stronger consensus rating and higher probable upside, analysts clearly believe Abiomed is more favorable than Glaukos.

Earnings and Valuation

This table compares Glaukos and Abiomed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30
Abiomed$840.88 million17.96$203.01 million$4.7470.42

Abiomed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Abiomed beats Glaukos on 12 of the 14 factors compared between the two stocks.

Glaukos (NYSE:GKOS) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Glaukos and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Glaukos-33.61%-7.99%-5.87%
NovoCure4.26%7.40%3.94%

Institutional & Insider Ownership

71.1% of NovoCure shares are owned by institutional investors. 8.7% of Glaukos shares are owned by company insiders. Comparatively, 5.1% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Glaukos has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glaukos and NovoCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Glaukos16102.00
NovoCure14402.33

Glaukos presently has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. NovoCure has a consensus target price of $139.2857, suggesting a potential upside of 5.45%. Given NovoCure's stronger consensus rating and higher probable upside, analysts clearly believe NovoCure is more favorable than Glaukos.

Earnings and Valuation

This table compares Glaukos and NovoCure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30
NovoCure$351.32 million38.51$-7,230,000.00($0.07)-1,887.00

Glaukos has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Summary

NovoCure beats Glaukos on 11 of the 14 factors compared between the two stocks.

Glaukos (NYSE:GKOS) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Glaukos and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Glaukos-33.61%-7.99%-5.87%
Penumbra-1.79%-0.12%-0.09%

Institutional & Insider Ownership

88.2% of Penumbra shares are owned by institutional investors. 8.7% of Glaukos shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Glaukos has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glaukos and Penumbra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Glaukos16102.00
Penumbra02402.67

Glaukos presently has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. Penumbra has a consensus target price of $279.00, suggesting a potential upside of 2.56%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Glaukos.

Earnings and Valuation

This table compares Glaukos and Penumbra's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30
Penumbra$547.41 million18.11$48.46 million$0.98277.58

Penumbra has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats Glaukos on 12 of the 14 factors compared between the two stocks.

Glaukos (NYSE:GKOS) and Hill-Rom (NYSE:HRC) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Glaukos and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Glaukos-33.61%-7.99%-5.87%
Hill-Rom7.74%22.71%8.01%

Earnings and Valuation

This table compares Glaukos and Hill-Rom's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30
Hill-Rom$2.88 billion2.60$223 million$5.5320.42

Hill-Rom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.8% of Hill-Rom shares are owned by institutional investors. 8.7% of Glaukos shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glaukos and Hill-Rom, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Glaukos16102.00
Hill-Rom01602.86

Glaukos presently has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. Hill-Rom has a consensus target price of $121.00, suggesting a potential upside of 7.14%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts clearly believe Hill-Rom is more favorable than Glaukos.

Volatility and Risk

Glaukos has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Hill-Rom beats Glaukos on 11 of the 14 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares Globus Medical and Glaukos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Glaukos-33.61%-7.99%-5.87%

Valuation & Earnings

This table compares Globus Medical and Glaukos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million8.51$155.21 million$1.6839.88
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30

Globus Medical has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.4% of Globus Medical shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by insiders. Comparatively, 8.7% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Globus Medical and Glaukos, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Glaukos16102.00

Globus Medical currently has a consensus price target of $66.40, suggesting a potential downside of 0.90%. Glaukos has a consensus price target of $66.3750, suggesting a potential downside of 20.16%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than Glaukos.

Risk and Volatility

Globus Medical has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.

Summary

Globus Medical beats Glaukos on 12 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares Haemonetics and Glaukos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Glaukos-33.61%-7.99%-5.87%

Valuation & Earnings

This table compares Haemonetics and Glaukos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.02$76.53 million$3.3135.37
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30

Haemonetics has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 8.7% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Haemonetics and Glaukos, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
Glaukos16102.00

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 23.70%. Glaukos has a consensus price target of $66.3750, suggesting a potential downside of 20.16%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Glaukos.

Risk and Volatility

Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.

Summary

Haemonetics beats Glaukos on 11 of the 14 factors compared between the two stocks.


Glaukos Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abiomed logo
ABMD
Abiomed
1.4$333.81-1.2%$15.10 billion$840.88 million73.36News Coverage
NovoCure logo
NVCR
NovoCure
1.5$132.09-0.3%$13.53 billion$351.32 million695.25Analyst Upgrade
Insider Selling
Penumbra logo
PEN
Penumbra
1.5$272.03-0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94-1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00-1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06-2.8%$5.95 billion$988.48 million56.55Gap Up
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$218.45-3.3%$5.93 billion$82.05 million-94.16Gap Up
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12-0.9%$5.92 billion$1.52 billion104.66
Inari Medical logo
NARI
Inari Medical
1.1$113.64-0.2%$5.54 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99-0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08-0.9%$5.09 billion$390.26 million-54.07
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$137.01-0.7%$4.77 billion$42.93 million-67.83
ICU Medical logo
ICUI
ICU Medical
1.5$204.19-0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76-1.3%$3.87 billion$214.55 million-69.51
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76-0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71-1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50-1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90-1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13-0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72-0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14-0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60-1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95-2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48-4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.